Sequential Skin Ltd

Based in the UK, Sequential Skin Ltd provides personalized skincare solutions by analyzing individual skin microbiomes through a comprehensive testing platform. Sequential Skin Ltd specializes in personalized skincare solutions by leveraging individual skin microbiome analysis. Founded in 2019 in London, In March 2026, Sequential Skin Ltd raised USD 3. 5 million in venture funding from Sparkfood, Corundum Systems Biology, Dermazone Holdings, SOSV, Scrum Ventures, and Innovate UK.

The firm is co-founded by Albert Dashi and Oliver Worsley, who also serves as CEO. Sequential Skin specializes in personalized skincare solutions derived from individual skin microbiomes. The company offers a comprehensive end-to-end microbiome testing platform that enables users to gain insights into their unique skin health. This platform includes a range of products such as the Microbiome Discover Kit, which analyzes a user’s skin microbiome, and the Skin Health Tracker, which allows customers to monitor changes over time.

Their services cater to various segments, including skincare, scalp care, oral care, and intimate care, aimed at consumers seeking tailored solutions for their specific skin concerns. The company primarily serves customers in North America and Europe, targeting health-conscious individuals interested in skincare solutions based on scientific research. Sequential Skin generates revenue through direct-to-consumer sales of its microbiome testing products and associated skincare solutions. The business model focuses on one-time purchases and potential subscription services for ongoing skin health monitoring and product recommendations.

Customers typically engage with the company by purchasing the Microbiome Discover Kit, which may include follow-up consultations or tailored product suggestions based on the initial testing results. The firm also explores partnerships with skincare retailers to expand its market reach. Specific pricing structures for individual products or services have been established to align with the premium nature of their offerings, reflecting the bespoke quality of their solutions. The company will use the March 2026 funding to develop an artificial intelligence-powered discovery engine built on a real-world clinical dataset and expand its testing infrastructure to accelerate skin health innovation.